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Background. Anxious and depressive symptoms are frequent in Systemic Sclerosis (SSc). Our objective is to assess their prevalence
and association with district and global disability and psychological variables.Methods. 119 SSc patients were assessed by Hospital
Anxiety Depression Scale (HADS). Clinical depression and anxiety were defined for HADS score cutoff ≥8. Patients were assessed
for psychological symptoms (RSES, COPE-NIV), hand (HAMIS, CHFDS, fist closure, and hand opening) and face disability
(MHISS, mouth opening), global disability, and fatigue (HAQ, FACIT). Results. Both depression and anxiety in SSc are 36%.
Depressive patients with comorbid anxiety have higher HADS-D score than patients with depression only (𝑃 = 0.001). HADS-
A and-D are positively correlated with global disability, hands and mouth disability, fatigue, self-esteem and avoidance coping
strategy, and, only HADS-A, also with social support (𝑃 < 0.05). By multiple regression, HADS-D is independently associated with
FACIT-F (𝑃 < 0.001), RSES (𝑃 < 0.001), and MHISS total score (𝑃 = 0.016), together explaining 50% of variance. HADS-A is
independently associated with RSES (𝑃 = 0.006), COPE-NIV SA (𝑃 = 0.003), COPE-NIV SS (𝑃 = 0.008), FACIT-F (𝑃 = 0.022),
and MHISS mouth opening (𝑃 = 0.029), explaining 41% of variance. Conclusions. In SSc depression and anxiety correlate to local
and global disabilities and psychological characteristics. Depressive patients with comorbid anxiety have higher level of depressive
symptoms.
1. Introduction
Systemic Sclerosis (SSc), characterized by skin, joint, and
muscle modifications, leads to disability and impairs health
related quality of life (QoL) [1].
As a consequence of chronicity, SSc patients report high
level of pain, fatigue, and impaired physical functioning
[2, 3]. SSc often disfigures the most visible and socially
relevant parts of the body like the face and the hands. These
changes may affect social relationships, cause functional
problems, and alter patient’s self-image, leading to body
image dissatisfaction, thus reducing QoL [4, 5].
In addition to physical impairments and symptoms, SSc
patients also report higher rates of anxiety and depression
(ranging from 18% to 65%) than general population and other
patients groups [6, 7].
In SSc, previous studies examining problems associated
with depression and anxiety reported various different cor-
relations. Depressive symptoms were related with reduction
of working ability, social activity and capacity to respond
to stressors, higher level of helplessness, pain, fatigue, social
support, emotional focused coping, and fear of disease pro-
gression [8, 9]. Roca et al. reported depression as correlated
to younger age, digital ulcers, and higher functional disability.
Correlations between depression and aspects of personality,
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psychosocial adjustment to illness, and lack of social support
[6] were also shown. In some studies, depressive symptoms
were linked to SSc severity [10–12], pulmonary restrictive
disease [13], fatigue [14], or other physical symptoms [10, 12].
Only one of them evaluated mood disorders according to
disease subsets [15], not showing any difference.
While anxiety has been largely studied in other chronic
diseases and in rheumatoid arthritis (RA) [16, 17], only
few studies addressed this problem in SSc patients [13, 15,
18–20], in which it was associated with education, joint
deformity, disease activity, disease duration [21], and gender
[19]. However, none of these studies evaluated the potential
effects of self-esteem, mouth, and hand disability on anxiety
and depression in SSc.
Only few works evaluated mood disorders in SSc accord-
ing to Hospital Anxiety and Depression Scale (HADS).
Baubet et al. used HADS only as a screening tool for anxiety
and depressive disorders in SSc patients then evaluated by
Mini International Neuropsychiatric Interview [13]. Nguyen,
assessing differences in HADS according to gender, did
not evaluate correlation between HADS scores and other
parameters [19].
The only study correlating HADS to psychological and
clinimetric parameters by a multivariate regression analysis
found fear of negative evaluation and overall interference
of SSc on activities as the most important contributions
to HADS-A and HADS-D, respectively, but not assessed
disability [20].
Data from the literature consistently suggest that in the
majority of subjects presenting both depressive and anxiety
symptoms, defined as comorbid cases, anxiety disorders are
primary to depression and that patients with anxiety are
at higher risk to develop major depression [22]. Depressive
patients with comorbid anxiety symptoms have a more
difficult course, with a decreased or a delayed response to
treatment [23]. Comorbidity of depression and anxiety, at the
best of our knowledge, was never evaluated in SSc patients.
Basing on all these data, a work aiming to systematically
assess a large panel of clinimetric and psychometric tools
and to individuate by multivariate regression analysis their
contribution to HADS scores is still lacking.
Thus, the objectives of the present study are to assess
the prevalence of depressive and anxiety symptoms in SSc;
to evaluate whether comorbid anxiety may lead to higher
level of depression; to assess the potential differences between
subsets; to evaluate the possible correlation of depression and
anxietywith hands and face involvement anddisability, global
disability, fatigue, and psychological characteristics.
2. Patients and Methods
One hundred nineteen SSc patients, fulfilling ACR criteria
[24] [14 men and 105 women; 74 with limited SSc (lSSc);
and 45 with diffuse SSc (dSSc)) [25]; age: 59.46 ± 13.87 years;
disease duration, calculated as the distance from the first
symptom after Raynaud’s Phenomenon: 10.74 ± 7.42 years],
were consecutively enrolled from the Division of Rheumatol-
ogy of the University of Florence.
Patients signed a written informed consent; the pro-
cedures were conducted in accordance with the 1975/83
Helsinki Declaration, and the study was approved by local
ethical committee.
2.1. Psychological Assessment. Hospital Anxiety and Depres-
sion Scale (HADS) is a reliable and valid self-report question-
naire for identifying and quantifying psychological distress
[26]. It is a self-rating scale consisting of 2 subscales: HADS-
A (anxiety) and HADS-D (depression). HADS includes 7
questions for each dimension, whose scores range from 0
(no depression, no anxiety) to 21 (maximal depression or
anxiety).
HADS was also administered to 50 healthy controls, age
and sex matched to SSc patients (4 men and 46 women,
age 52.10 ± 9.0, not significantly different from SSc patients
for male: female ratio and for age), enrolled by a general
practitioner among the patients visiting his outpatients clinic,
without rheumatic or chronic diseases.
The evaluation was based on cutoff score ≥8 in HADS-A
and HADS-D, as indicated in autoimmune diseases [26] and
in general population [27].
Rosenberg Self-Esteem Scale (RSES) is used to assess global
self-esteem [28].
Coping Orientation to Problems Experienced-New Italian
Version (COPE-NVI) is utilized to assess coping, the use of
skills and strategies adopted to face stressful and difficult
events. COPE-NVI is a 60-item self-report questionnaire
exploring 15 different types of coping, grouped in 5 large
essentially independent dimensions: Social Support (SS),
Avoidance Strategies (AS), Positive Attitude (PA), Problem
Solving (PS), and Transcendent Orientation (TO) [29].
2.2. Assessment of HandDisability andMobility. HandMobil-
ity in Scleroderma Test (HAMIS) is a performance-based test,
composed of 9 items, all related to movements that are part
of daily occupations [30]. Validity of the Italian version of
HAMIS in SSc patients was demonstrated [31].
Cochin Hand Functional Disability Scale (CHFDS) is a
self-report questionnaire, measuring hand functional ability
in performing 18 daily tasks of living, reliable and valid in
patients with SSc. [32, 33]. Fist Closure and Hand Opening.
Fist closure is valued as the distance between the fingertip
of the third finger and tenar eminence when making a fist,
and hand opening as the distance between the fingertip of
the third finger, when extended, and the table. Bothmeasures
are reported in centimeters and as means of two consecutive
measurements.
2.3. Assessment of Face Disability and Mobility. The func-
tional involvement of face and mouth is assessed by the
Mouth Handicap in Systemic Sclerosis (MHISS) scale and
mouth opening.
Mouth Handicap in Systemic Sclerosis Scale (MHISS)
assessing the handicap associated with mouth disability in
SSc consists in 12 items (each scored 0–4, with a total score
ranging from 0 to 48) divided into 3 subscales: subscale
1 examines handicap related to reduced mouth opening;
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subscale 2 assesses handicap related to sicca syndrome;
subscale 3 examines aesthetic concerns [34, 35].
Maximal Oral Aperture is measured as the distance
between the lower and upper lips vermilion line while the
patient opens up mouth as widely as possible. The measure
is reported in centimeters and as mean of two consecutive
measurements.
2.4. Assessment of Global Disability and Fatigue. Health
Assessment Questionnaire (HAQ) [36] is a self-report ques-
tionnaire assessing global disability. Functional Assessment of
Chronic Illness Therapy-Fatigue (FACIT-F) evaluates physical
and functional consequences of fatigue in performing daily
activities [37].
2.5. Statistical Analysis. Descriptive statistics are provided as
mean ± standard deviation for continuous variables and as
number and percentages for binomial variables. Continuous
variables were tested with the Kolmogorov-Smirnov test for
normality. In SSc patients and controls, student’s t-test was
used to compare scores of HADS-A and HADS-D and to
evaluate scores of HADS-D in subjects with anxiety (scoring
≥8 at HADS-A) in respect of those without anxiety; percent
of depressive and anxious symptoms were compared with
Fischer exact test. Clinical, clinimetric, and anthropometric
characteristics of lSSc and dSSc groups were compared by
Fisher exact test or 𝑋2 test for binomial variables and t
test and Mann-Whitney test for continuous variables, when
appropriate. For correlations ofHADS-DandHADS-A scores
with clinical, clinimetric, and anthropometric characteristics
Spearman’s or Pearson correlations tests were used, when
appropriate. Variables shown as significantly correlated with
HADS-D and HADS-A were entered in hierarchical multiple
regression models with HADS-D and HADS-A scores as the
dependent variables. For all statistical tests, the threshold
of significance was set at a P value < 0.05. All analyses
were performed using SPSS version 20.0 for Windows (SPSS,
Chicago, IL, US.)
3. Results
Theclinical, clinimetric, and anthropometricmeasures of SSc
patients are presented in Table 1.
3.1. HADS Scores. In SSc group, HADS-D (6.14 ± 3.97) and
HADS-A (6.66 ± 4.09) scores were higher than in healthy
controls (4.72 ± 2.88 and 5.16 ± 3.05) (P < 0.05 for both
comparisons).
Basing on a cutoff score ≥8 in both HADS subscales [36],
both rates of depression and anxiety in 6 of the whole SSc
group were 36%. Fifteen out of 119 patients (13%) had only
depression, 15/119 (13%) presented only anxiety, and 28/119
(23%) had both depression and anxiety.
Depressive patients with comorbid anxiety had signifi-
cantly higher HADS-D score than patients with depression
only (11.39 ± 1.57 versus 9.4 ± 1.64; P = 0.001). In healthy
controls, the rates of depression and anxiety were 10% (5/50)
and 20% (10/50), lower than in SSc (P < 0.001 for HADS-D
and < 0.05 for HADS-A).
In controls, the copresence of depression and anxiety,
found in 2/50 subjects (4%), was lower than in SSc (P = 0.001).
In controls, depressive subjects with comorbid anxiety
had significantly higher HADS-D score than subjects with
depression only (9.5 ± 2.1 versus 4.92 ± 2.86; P = 0.001).
3.2. Comparison between lSSc and dSSc (Table 1). No signif-
icant difference in HADS-D, HADS-A, RSES, COPE NIV
subscales, and COPE NIV total score between lSSc and
dSSc was found. Hand and mouth disability, global disability,
and fatigue were significantly higher and hand and mouth
mobility significantly lower in dSSc than in lSSc (P < 0.05 for
all comparisons).
3.3. Correlations of Symptoms of Depression and Anxiety
with Psychological, Physical Variables. Global, Hands Dis-
ability, and Face Involvement. HADS-D was significantly
positively correlated with COPE-NVI AS (P = 0.001), right
and left HAMIS (P = 0.013 and 0.020, resp.), FACIT-F,
HAQ, MHISS total, MHISS mouth opening, MHISS sicca
syndrome,MHISS aesthetic concerns, andCHFDS (P < 0.001
for all variables) and negatively with RSES (P < 0.001 ) and
mouth opening (P = 0.16).
HADS-A was significantly positively correlated with
FACIT-F (P < 0.001), COPE-NVI AS (P < 0.001), HAQ (P =
0.001), MHISS total (P < 0.001) , MHISS mouth opening (P <
0.001), MHISS sicca syndrome (P = 0.001), MHISS aesthetic
concerns (P = 0.004), and CHFDS (P = 0.032) and negatively
with RSES (P < 0.001) and COPE-NIV total score (P = 0.01).
No correlation was found between HADS-A and HADS-D
and other variables (Table 2).
3.4. Hierarchical Multiple Linear Regression. In SSc patients,
by the hierarchical multiple linear regression models,HADS-
D was significantly associated with FACIT-F (𝐵 = 0.42; 𝑡 =
5.38; P < 0.001), RSES (𝐵 = −0.29; 𝑡 = −3.62; P < 0.001), and
MHISS total score (𝐵 = 0.20; 𝑡 = 2.64; P = 0.016), which,
together, explained50.3% of the variance in HADS-D score
(FACIT-F:38.2% ; RSES: 9.7%; MHISS total score: 2.4%).
HADS-A was significantly associated with RSES (B =
−0.24; 𝑡 = −2.79; P = 0.006), COPE-NIV SA (B = 0.25; 𝑡
= 3.08; P = 0.003), COPE-NIV SS (B = 0.20; 𝑡 = 2.70; P =
0.008), FACIT-F (B = 0.20; t = 2.33; P = 0.022), and MHISS
mouth opening (B = 0.18; 𝑡 = 2.21; P = 0.029). Together, these
variables explained41.2% of the variance in HADS-A score
(RSES: 23.9%, COPE-NIV SA: 7.5%, COPE-NIV SS: 3.9%,
FACIT-F: 3.7%, and MHISS mouth opening: 2.2%).
4. Discussion
Depression and anxiety, frequent in patients with rheumatic
diseases, are associated in SSc with impairment of QoL and
sexual functioning, nonadherence to treatment regimes, and
increased request for healthcare [7, 38, 39].
In SSc patients, our results indicate rates of depression
and anxiety (36% each) higher than healthy controls (whose
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Table 1: Clinical, clinimetric, and anthropometric characteristics of SSc patients.
SSc lSSc dSSc 𝑃 value (lSSc versus dSSc)
Age (years) 59.92 ± 13.49 60.28 ± 13.25 59.31 ± 14.01 NS
Disease duration (years) 10.58 ± 7.42 10.28 ± 8.06 11.05 ± 6.39 NS
HADS-D 6.14 ± 3.97 5.96 ± 3.89 6.44 ± 4.11 NS
HADS-A 6.66 ± 4.09 6.57 ± 3.84 6.80 ± 4.11 NS
RSES 21.30 ± 4.20 21.23 ± 4.16 21.42 ± 4.31 NS
COPE NVI SS subscale 24.46 ± 7.15 24.88 ± 6.95 23.82 ± 7.47 NS
COPE NVI AS subscale 22.02 ± 5.06 22.26 ± 5.14 21.64 ± 4.97 NS
COPE NVI PA subscale 29.90 ± 6.95 30.13 ± 6.93 29.55 ± 7.06 NS
COPE NVI PS subscale 24.92 ± 5.64 24.72 ± 5.22 25.23 ± 6.30 NS
COPE NVI TO subscale 24.12 ± 5.28 23.76 ± 4.90 24.66 ± 5.84 NS
COPE NIV total score 127.97 ± 28.83 129.97 ± 34.23 124.89 ± 17.42 NS
Right HAMIS 5.19 ± 5.36 3.82 ± 4.62 7.40 ± 5.77 <0.001
Left HAMIS 5.03 ± 5.12 3.58 ± 4.08 7.40 ± 5.77 <0.001
CHFDS 10.68 ± 13.10 9.60 ± 15.36 12.51 ± 11.25 <0.05
Right hand opening 3.40 ± 1.34 3.65 ± 1.29 3.01 ± 1.34 <0.05
Left hand opening 3.28 ± 1.38 3.49 ± 1.44 2.95 ± 1.24 <0.05
Right fist closure 0.79 ± 1.40 0.53 ± 1.17 1.19 ± 1.61 <0.01
Left fist closure left 0.82 ± 1.42 0.51 ± 1.19 1.30 ± 1.62 <0.001
MHISS total 18.12 ± 11.21 16.26 ± 11.13 21.18 ± 10.77 <0.05
MHISS mouth opening 8.14 ± 6.09 6.91 ± 631 10.18 ± 5.18 0.001
MHISS Sicca syndrome 6.96 ± 5.26 6.92 ± 4.91 7.02 ± 5.85 NS
MHISS aesthetic concerns 3.43 ± 2.93 3.08 ± 3.00 4.00 ± 2.76 NS
Mouth opening 3.89 ± 0.10 4.14 ± 0.88 3.47 ± 1.04 0.001
HAQ 0.63 ± 0.65 0.55 ± 0.70 0.76 ± 0.53 <0.05
FACIT-F 14.08 ± 9.62 12.77 ± 9.58 16.20 ± 9.41 <0.05
Legend: values are presented as mean ± SD; SSc: systemic sclerosis; NS: not significant; HADS: Hospital Anxiety and Depression Scale; RSES: Rosenberg Self-
Esteem Scale; COPE NIV: Coping Orientation to Problems Experienced-New Italian Version (SS: social support subscale; AS: avoidance strategies subscale;
PA: positive attitude subscale; PS: problem solving subscale; TO: transcendent orientation subscale); HAMIS: Hand Mobility In Scleroderma Test); CHFDS:
Cochin Hand Functional Disability Scale; MHISS: Mouth Handicap in Systemic Sclerosis Scale; HAQ: Health Assessment Questionnaire; FACIT-F: Functional
Assessment of Chronic Illness Therapy-Fatigue Scale.
rates of depression and anxiety were 10% and 20%, resp.).
These data are in agreement with previous results obtained
by HADS in SSc [16] and higher than in European general
population, where depression and anxiety range from 4.6 %
to 23% and from 9.6% to 21%, respectively [40, 41].
As far as we know, comorbidity between anxiety and
depressive conditions was never evaluated in SSc patients. In
our study, it was present in 23% of SSc patients, thus very
close to the rate already demonstrated in general population
and in other patient groups [16, 17]. We also found that
depressive patients with comorbid anxiety present signifi-
cantly higher HADS-D scores than those with depression
only, in agreement with data present in other patients groups
[16, 17]. Concordantly with previous studies, no difference in
depressive and anxiety symptoms between lSSc and dSSc was
found, suggesting thatmoods disordersmay be present in SSc
independently from the disease subsets [15].
In our study, depressive symptoms were significantly
correlated with global disability, hands and mouth disability,
fatigue, self-esteem, and avoidance strategy in coping.
Anxiety was correlated with self-esteem, high level of
fatigue, avoidance strategy, social support, and with global,
face, and hands disability.
In SSc, only few studies assessed factors independently
related to anxiety and no studies assessed impact of hands and
face disability on anxiety [13, 14, 18, 21].
The significant correlation between depression and anx-
iety with hands disability may indicate that an increased
need of help in daily life occupations or the experiencing of
helplessness could favor the development of depressive and
anxiety disorders in SSc patients.
In agreement with data shown in RA, [38], in SSc, depres-
sive and anxiety symptoms correlate with coping avoidance
strategy. In SSc patients, the modifications of the most visible
and socially relevant body parts, such as hands and face, may
lead to difficulty in social relationships and, consequently, to
avoidance behaviors and social anxiety [42].
Our data show a direct correlation between the social
support and anxiety. Previous studies on the relationship
between social support and anxiety provided contradictory
results. Some works indicated that individuals with less
perceived social support scores reported higher levels of
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Table 2: Correlations of HADS-D and HADS-A with psychological and physical variables.
HADS-D HADS-A
𝑃 value 𝑟 𝑃 value 𝑟
Age (years) NS — NS —
Disease duration (years) NS — NS —
RSES <0.001 −0.555 <0.001 −0.483
COPE NIV SS subscale NS — <0.05 0.291
COPE NIV AS subscale 0.001 0.304 <0.001 0.494
COPE NIV PA subscale NS — NS —
COPE NIV PS subscale NS — NS —
COPE NIV TO subscale NS — NS —
COPE NIV total score NS — 0.01 −0.243
HAMIS right 0.01 0.228 NS —
HAMIS left <0.05 0.213 NS —
HAMIS mean 0.01 0.223 NS —
CHFDS <0.001 0.338 <0.05 0.199
Right hand opening NS — NS —
Left hand opening NS — NS —
Right fist closure NS — NS —
Left fist closure NS — NS —
MHISS mouth opening <0.001 0.390 <0.001 0.328
MHISS Sicca syndrome <0.001 0.418 0.001 0.292
MHISS aesthetic concerns <0.001 0.317 <0.05 0.259
MHISS tot <0.001 0.482 <0.001 0.365
Mouth opening 0.01 −0.228 NS —
HAQ <0.001 0.406 0.001 0.310
FACIT <0.001 0.616 <0.001 0.440
Legend: values are presented as mean ± SD; SSc: systemic sclerosis; NS: not significant; 𝑃 and 𝑟 values are presented as Pearson’s correlation.
HADS: Hospital Anxiety and Depression Scale; RSES: Rosenberg Self-Esteem Scale; COPE NIV: Coping Orientation to Problems Experienced-New Italian
Version (SS: social support subscale; AS: avoidance strategies subscale; PA: positive attitude subscale; PS: problem solving subscale; TO: transcendent orientation
subscale); HAMIS: Hand Mobility In Scleroderma Test; CHFDS: Cochin Hand Functional Disability Scale; MHISS: Mouth Handicap in Systemic Sclerosis
Scale; HAQ: Health Assessment Questionnaire; FACIT-F: Functional Assessment of Chronic Illness Therapy-Fatigue Scale.
anxiety [43, 44], while other surveys [45] did not find any
correlation between social support and anxiety or found a
negative effect of social support [46]. Further studies are
needed to explore such correlation and to identify the aspects
of the social support whichmay impact negatively on anxiety.
The correlation of fatigue both to anxiety and to depres-
sion is not surprising. In fact, the symptom, that is frequent
and mainly due to muscle-skeletal involvement [47, 48],
may lead to anxiety and depression by diminishing mobility,
independence, and ability to engage in social activities.
In our patients, self-esteem, correlated to anxiety and
depression, may be potentially impaired both by the reduc-
tion of physical functioning, causing difficulties in per-
forming daily activities, and by the changes in face and
hands [49]. In women with SSc, self-esteem pertaining to
appearance was found lower than in burn victims and related
to depressive and anxious symptoms [50, 51]. Hierarchical
multiple regression analyses revealed that fatigue, firstly, self-
esteem, and mouth disability were independent related to
depression. Self-esteem, and, secondarily, avoidance strategy,
social support, fatigue, and mouth disability were indepen-
dently associated with anxiety.
Previous studies examining variables related to depressive
symptoms did not include the analysis of self-esteem and
district disability. These surveys found younger age, digital
ulceration, global disability, aspects of personality [6], social
support [6, 9], helplessness [8, 9], sense of coherence [8], pain,
fatigue, emotional-focused coping, and fear of progression
[9] to be independently associated with depression [6, 8, 9].
These works, moreover, did not evaluate anxiety together
with depression. Our study is the first evaluating bivariate
association of district and global disability and psychological
variables with anxiety in SSc and using stepwise regression
analyses to identify factors independently related to anxiety.
A limitation of our study is the cross-sectional design,
that does not allow us to draw conclusions about prospective
association between disease-related functional impairment
and psychological distress among SSc patients.
HADS is a reliable and valid test to screen for depression
and anxiety, easy to be used and scored, able to exclude
somatic items [52, 53], and potentially useful in everyday
practice to assess SSc subjects. Patients resulting positive for
the screening should be addressed to a specialist, undergo
a more structured clinical interview for further assessment,
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and be treated by psychoeducational or pharmacological
interventions.
Some interventions may be useful to reduce SSc-related
distress. Social interaction skills training programs [54],
cognitive behavioral therapy for social anxiety [55], and
educational and psychotherapy interventions [56] reduced
social avoidance and increased self-esteem in social setting
for other patients groups and decreased pain, disability,
fatigue, and physician visits in patients with other rheumatic
diseases. Thus, they could be expected to have similar effects
in SSc as well, both if used alone or in combination with
pharmacological therapy.
4.1. In Conclusion. In SSc patients, depression and anxiety
are common and are correlated both with local and global
disabilities and to psychological characteristics. Bymultivari-
ate analysis, depressive symptoms are associated with fatigue,
and self-esteem and avoidance strategies of coping are asso-
ciated with anxiety. SSc patients with depression associated
with anxiety have higher level of depressive symptoms.Thus,
their treatment should be focused both to depressive and
anxiety components. However, future research is needed to
confirmHADS as a useful instrument of routine screening for
depressive and anxiety disorders and to evaluate the impact of
treatment and psychotherapy interventions on psychological
distress in SSc patients.
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